Nimbus Therapeutics, LLC ("Nimbus Therapeutics" or "Nimbus"), a biotechnology company that designs and develops breakthrough medicines through its powerful computational drug discovery engine, today ...

Metal-based nanoparticles are transforming food packaging by enhancing antimicrobial protection, shelf life, and barrier ...

Boehringer Ingelheim and Tessellate Bio have entered into a partnership worth over €500m to develop oral precision medicines ...

Boehringer Ingelheim has signed a €500m ($572m) agreement with UK-based biotech Tessellate Bio to co-develop targeted cancer ...

Ingelheim: Boehringer Ingelheim and Tessellate Bio, a precision oncology company, have entered into a research collaboration ...

A team was able to edit the DNA of Lactobacillus strains directly without a template from other organisms. This technique is indistinguishable from natural variation and enabled the researchers to ...

Among the major classes of RNAs in the cell, tRNAs remain the most difficult to characterize via deep sequencing approaches, as tRNA structure and nucleotide modifications can each interfere with cDNA ...

Nimbus Therapeutics announced the launch of a first-in-human clinical trial for NDI-219216, its investigational Werner ...